Health

  • March 30, 2026

    5th Circ. Seems Open To Reviving Eyemart Class Action

    A Fifth Circuit panel seemed open to reviving a class action accusing glasses retailer Eyemart Express LLC of selling sensitive personal health information to social media giant Meta, asking Monday why dismissal was appropriate given the complexity of the case.

  • March 30, 2026

    Don't Set Special IP Rules For 'Skinny Labels,' Justices Told

    Drugmakers, industry groups, hospitals and scholars have urged the U.S. Supreme Court to uphold a decision letting a patent suit proceed over a generic drug using a so-called skinny label, saying the generics company is seeking unwarranted special protections that would upend patent law.

  • March 30, 2026

    Fla. Hospital System Patients Get Class Cert. Denied

    A Florida federal court refused to certify a class of consumers in a case accusing Health First Inc. of locking in patients and blocking competition from rival hospital systems, after finding a number of issues, including potential differences between proposed class members.

  • March 30, 2026

    Foreseeability 'Tricky' For Yale Doc's 1981 Act, Court Told

    Yale New Haven Health Services Corp. on Monday asked a Connecticut state judge to strike seven of 10 counts from a lawsuit accusing a doctor of using his own sperm to impregnate a fertility patient, saying it was not foreseeable in 1981 that technology might some day reveal the doctor's actions.

  • March 30, 2026

    Product Liability Q1 Regulatory Roundup

    In the first three months of 2026, executive orders and other regulatory actions by the Trump administration have taken on products with "Made in America" labeling, called for the increased manufacture of the herbicide ingredient glyphosate, and addressed what e-cigarette flavors could receive the U.S. Food and Drug Administration's approval, among others.

  • March 30, 2026

    FCA Qui Tams Are Unconstitutional, Eli Lilly Tells Justices

    The False Claims Act's whistleblower provisions are unconstitutional, drugmaker Eli Lilly has told the U.S. Supreme Court, asking it to overturn a Seventh Circuit decision upholding a $183 million trial win for a whistleblower who claimed the drug company hid how much it charged for Medicaid-covered drugs. 

  • March 30, 2026

    5th Circ. Calls Pharmacy GLP-1 Args 'Tough Pills To Swallow'

    A Fifth Circuit panel pushed multiple compounding pharmacies to explain why they should get to compound lucrative drugs used for weight loss, including Ozempic, saying Monday that its options if it sides with the pharmacies are "tough pills to swallow."

  • March 30, 2026

    Eye Doctor Appeals Microcaptive Tax Payments At 5th Circ.

    An eye doctor and his wife asked the Fifth Circuit to overturn a U.S. Tax Court decision from last year that affirmed Internal Revenue Service penalties and payments associated with their ophthalmology practice's microcaptive insurance arrangements.

  • March 30, 2026

    Steward Health Creditor Trustee Sues Aetna For $6.4M

    The leader of a creditor litigation trust in Steward Health Care's bankruptcy case has launched an adversary proceeding in Texas bankruptcy court against Aetna Health, saying the insurer has refused to pay $6.36 million owed to hospitals formerly owned by Steward.

  • March 30, 2026

    FTC Says Anesthesia Group Cheered While Raising Prices

    The Federal Trade Commission pushed back against a bid from U.S. Anesthesia Partners to avoid facing trial on claims that it monopolized the market through a rollup strategy, saying the company celebrated its ability to dramatically increase prices.

  • March 30, 2026

    Cleary-Led Blackstone Wraps Record $6.3B Life Sci Fund

    Private equity giant Blackstone, led by Cleary Gottlieb Steen & Hamilton LLP, revealed Monday that it wrapped its sixth life sciences fund after securing $6.3 billion of capital commitments, marking what the firm says is the largest private life sciences fund ever raised.

  • March 30, 2026

    Eli Lilly's $2.75B Pact Is Latest In AI Drug Discovery Push

    Eli Lilly and Co. has agreed to a partnership with artificial intelligence-driven drug discovery company Insilico that could be worth up to $2.75 billion, amid an expanding category of collaboration fueled by pharmaceutical giants seeking accelerated paths to new treatments. 

  • March 30, 2026

    TriZetto's $70M Trade Secret Verdict Upheld, Total Award Cut

    A New York federal judge has upheld a $70 million compensatory damages verdict for the TriZetto Group in a long-running trade secret fight against Syntel Inc., while also cutting punitive damages to about $140 million and awarding TriZetto more than $12 million in attorney fees.

  • March 30, 2026

    J&J Unit Wants Forensic Exam Of Ex-Director's Devices

    A Johnson & Johnson subsidiary urged a New Jersey federal court to order a former associate director to submit to a court-supervised forensic inspection of any device or account in which she could have stored confidential information it claims she downloaded in order to start her own competing company.

  • March 30, 2026

    Justices Pass On FCA Suit Alleging Quest Diagnostics Fraud

    The U.S. Supreme Court rejected on Monday a former Quest Diagnostics Inc. compliance officer's bid for review of the dismissal of a long-running False Claims Act suit against the medical testing company.

  • March 30, 2026

    Justices Reject TM Appeal Tied To 'Use In Commerce'

    The U.S. Supreme Court on Monday declined to take up an appeal challenging a Ninth Circuit ruling that upheld a multimillion-dollar default judgment based largely on statements defendants made in trademark applications.

  • March 27, 2026

    Elizabeth Holmes Gets 11-Year Prison Sentence Cut By A Year

    A California federal judge has shaved off a year from convicted ex-Theranos CEO Elizabeth Holmes' 11-year-and-three-month prison sentence for securities fraud due to recent sentencing guideline amendments, reducing her time behind bars by one year, instead of the two years she requested, amid objections by prosecutors.

  • March 27, 2026

    Eye Clinic's Hurricane Damage Suit Sent To Territorial Court

    A federal judge in the U.S. Virgin Islands has sent back to territorial court an ophthalmology clinic's lawsuit seeking punitive damages from its insurers that allegedly underpaid claims resulting from Hurricane Maria, which swept through the Caribbean in 2017 and caused about $1 million of lost income and damage to its property.

  • March 27, 2026

    Eli Lilly Keeps Most Of Weight Loss Drug Copy Suit Alive

    A California federal judge has refused to throw out a lawsuit accusing a pair of telehealth companies of making copies of Eli Lilly's obesity and type 2 diabetes drugs but agreed to trim the case.

  • March 27, 2026

    NC Biz Court Bulletin: Judge Exits, Duke Ducks Climate Suit

    The North Carolina Business Court saw an unexpected shakeup with one judge's retirement, rendered a pivotal decision in a first-of-its-kind climate change case against Duke Energy and oversaw a trial between the feuding owners of a commercial bed skirt company.

  • March 27, 2026

    5th Circ. Won't Revive Ex-Health IT Co. Worker's Bias Suit

    The Fifth Circuit upheld a healthcare information technology provider's win over a Black former manager's lawsuit claiming she was fired for complaining that a white male colleague was treated better, saying she couldn't overcome the company's rationale for letting her go.

  • March 27, 2026

    Hospital System Beats Most Of REIT's $50M Floodwall Suit

    A New York federal judge on March 27 mostly tossed a real estate investment trust's $50 million suit against the New York City Health and Hospitals Corp. and the NYC Economic Development Corp. over the design of a proposed floodwall for a downtown Manhattan life sciences campus project.

  • March 27, 2026

    Skincare Co. Says ITC Ruling Backs Ending PTAB Challenge

    Skin products company Hydrafacial has argued U.S. Patent and Trademark Office Director John Squires should turn down a rehearing request from rival Sinclair Pharma over Squires' order de-instituting a challenge to Hydrafacial's patent, saying a U.S. International Trade Commission decision upholding the same patent supports the director's move.

  • March 27, 2026

    Sens. Push Bill To Equip VA For Psychedelic Therapies

    A bipartisan group of U.S. senators has introduced legislation to broaden veterans' access to emerging therapies, including psychedelic-assisted treatments, that may be effective in addressing post-traumatic stress disorder and other mental health issues.

  • March 27, 2026

    Biopharma's Brass Hid Anxiety Drug Trial Risks, Investor Says

    Vistagen Therapeutics' current and former top brass have been hit with a derivative shareholder suit in California federal court alleging they overstated its clinical trial for a novel, anti-anxiety drug while hiding unpredictable placebo responses and other known risks, before the phase ultimately failed, causing a stock price collapse. 

Expert Analysis

  • How 11th Circ.'s Zafirov Decision Could Upend Qui Tam Cases

    Author Photo

    Oral argument before the Eleventh Circuit last month in U.S. ex rel. Zafirov v. Florida Medical Associates suggests that the court may affirm a lower court's opinion that the qui tam provisions of the False Claims Act are unconstitutional — which could wreak havoc on pending and future qui tam cases, say attorneys at Morgan Lewis.

  • Key Trends For Life Sciences Cos. To Watch In 2026

    Author Photo

    Following a year of drastic change at the U.S. Food and Drug Administration, two themes are likely to drive the coming year — a commitment to lowering the cost of drugs and an inherent tension between the priorities of the health agencies and the broader administration, say attorneys at Sheppard Mullin.

  • Series

    Muay Thai Makes Me A Better Lawyer

    Author Photo

    Muay Thai kickboxing has taught me that in order to win, one must stick to one's game plan and adapt under pressure, just as when facing challenges by opposing counsel or judges, says Mark Schork at Feldman Shepherd.

  • The Next Pressure Point In Digital Health: Informed Consent

    Author Photo

    Two new federal digital health initiatives will usher in a new era where virtual care, software-enabled devices and home-based monitoring are integrated into care and reimbursement models, with the impact of shifting rules and opportunities felt most immediately in the context of informed consent, says Kimberly Chew at Husch Blackwell.

  • Series

    Law School's Missed Lessons: Intentional Career-Building

    Author Photo

    A successful legal career is built through intention: understanding expectations, assessing strengths honestly and proactively seeking opportunities to grow and cultivating relationships that support your development, say Erika Drous and Hillary Mann at Morrison Foerster.

  • 4 Trends Shaping Drug And Medical Device Law For 2026

    Author Photo

    2025 saw some significant legal developments with potential impact for drug and device manufacturers, ranging from growing skepticism in science and regulatory entities to new regulation of artificial intelligence, say attorneys at Faegre Drinker.

  • Key Trends In Healthcare Antitrust In 2025

    Author Photo

    The healthcare industry braced for significant antitrust enforcement shifts last year driven by a change in administration, and understanding the implications of these trends is critical for healthcare organizations' risk management and strategic decision-making in the year ahead, say attorneys at Michael Best.

  • The 5 Most Important Bid Protest Decisions Of 2025

    Author Photo

    In a shifting bid protest landscape, five decisions in 2025 from the Federal Circuit, the U.S. Court of Federal Claims and the U.S. Government Accountability Office that addressed bedrock questions about jurisdictional reach and the breadth of agency discretion are likely to have a lasting impact, say attorneys at Bradley Arant.

  • Food Industry Braces For MAHA And Other Challenges In 2026

    Author Photo

    After the Make America Healthy Again movement kept the U.S. Food and Drug Administration under pressure in 2025, actions in the food safety space are likely to continue this year, including updated Supplemental Nutrition Assistance Program dietary guidelines and processed food definitions, say attorneys at Wiley.

  • Preparing For Congressional Investigations In A Midterm Year

    Author Photo

    2026 will be a consequential year for congressional oversight as the upcoming midterm elections may yield bolder investigations and more aggressive state attorneys general coalitions, so companies should consider adopting risk management measures to get ahead of potential changes, say attorneys at Morgan Lewis.

  • A Meaningful Shift In FDA's Biosimilarity Analysis

    Author Photo

    The U.S. Food and Drug Administration's potential pivot away from routinely requiring comparative efficacy studies for interchangeable biosimilar applications would not lower regulatory standards, but instead allow applicants to allocate resources toward establishing more probative evidence, says Theodore Thompson at Stinson.

  • Employment Immigration Trends And Challenges For 2026

    Author Photo

    U.S. companies competing for global talent should brace for a turbulent 2026, with greater compliance burdens, higher costs and the probability of workforce disruptions at every stage of the immigration process, from visa petitions to work authorization renewals, say attorneys at Duane Morris.

  • Top 5 Antitrust Issues For In-House Counsel To Watch In 2026

    Author Photo

    With Trump administration enforcement policy having largely taken shape last year, antitrust issues that in-house counsel should have on the radar range from scrutiny of technology-assisted pricing to the return of merger remedies, say attorneys at Squire Patton.

  • 4 Developments That Defined The 2025 Ethics Landscape

    Author Photo

    The legal profession spent 2025 at the edge of its ethical comfort zone as courts, firms and regulators confronted how fast-moving technologies and new business models collide with long-standing professional duties, signaling that the profession is entering a period of sustained disruption that will continue into 2026, says Hilary Gerzhoy at HWG Law.

  • Navigating AI In The Legal Industry

    Author Photo

    As artificial intelligence becomes an increasingly integral part of legal practice, Law360 guest commentary this year examined evolving ethical obligations, how the plaintiffs bar is using AI to level the playing field against corporate defense teams, and the attendant risks of adoption.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.